Contact
Please use this form to send email to PR contact of this press release:
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
TO: